伴随全球抗体药物研发迭代加速,多特异性药物经历多年基础科研沉淀,正式走出实验室,实现从早期科学概念向临床开发、商业化落地的跨越式发展。全球范围内,PD‑1/VEGF 双抗交出对标现有标准疗法的头对头临床关键数据,改写肿瘤治疗格局;双特异性 ADC、靶向自免靶点 TL1A 双抗、三特异性 T 细胞衔接器等多款创新分子快速推进临床,不断拓展抗体药物的治疗边界。
与此同时,行业也面临诸多现实挑战:大量多抗管线扎堆申报,同质化竞争日趋激烈,真正经过临床验证的技术路径仍然有限;分子构型设计、工艺开发、规模化生产 CMC 环节依旧是制约产品走向成功的核心卡点;全球多特异性药物研发力量快速崛起,越来越多创新资产获得国际药企与投资机构的关注,但不同创新生态之间仍存在信息差,跨境技术合作、授权交易机遇与风险并存。放眼未来 5‑10 年,除火热的肿瘤与免疫赛道外,多特异性药物能否在其他疾病领域实现突破,同样是全行业高度关切的议题。
在此背景下,11月17日20:00,《大国新药·国际版》第3期节目将聚焦“从双抗到三抗:全球新药创新的下一波浪潮”,集结五位重磅嘉宾,共同探寻多特异性药物的真实价值、差异化创新机会与跨境合作的可行路径。
主持人:
-唐钧,ISWT Community创始人
嘉宾:
-李竞,橙帆医药创始人、CEO
-Stephen Yoder, Red Ridge Bio CEO
-Liangsu Wang, Caldera Therapeutics联合创始人、CEO
-Zhen Su, Marengo Therapeutics 总裁、CEO
-Dandan Dong, TCGX Capital 管理合伙人
嘉宾简介向上滑动查看
Jing Li
Founder and CEO, VelaVigo
Dr. Jing Li is the founder and CEO of VelaVigo. Under his leadership, the company has raised $160 million, out-licensed two preclinical programs in deals with total value of more than $1.2 billion, and advanced two first-in-class programs into global clinical trials.
Before founding VelaVigo, Dr. Li was Senior Vice President at WuXi Biologics. He previously served as Senior Manager of Portfolio & Alliance Management at the Novartis Biologics Center, Lab Head and Program Team Head at Novartis Oncology, and Senior Scientist and Project Leader at Wyeth (now Pfizer).
Dr. Li has more than 30 years of experience in antibody engineering and 25 years in industry drug discovery and development. He has filed more than 70 patent applications and authored more than 20 publications, and Harvard Business School has adopted VelaVigo’s founding journey as a case study. He received his MD and PhD in molecular immunology and oncology from Peking University Health Science Center, his MBA from the Yale School of Management, and completed postdoctoral training at Tufts University.
Stephen Yoder
CEO, Red Ridge Bio
Stephen Yoder is President and CEO of RedRidge Bio, a combinatorial biology company developing bispecific antibodies, including biparatopics that bind two epitopes on one target, in oncology and autoimmunity. RedRidge runs a fully integrated East-West R&D model, with strategy anchored in the U.S. and Basel, Switzerland, and execution in Shanghai.
The company has an oncology-focused R&D collaboration with Pierre Fabre and a proprietary pipeline in oncology and autoimmune disease, with its first IND forecast for 2027. RedRidge is Series A-funded in a round co-led by Versant and NEA.
Previously, Mr. Yoder was CEO of Pieris Pharmaceuticals for 15 years and General Counsel and head of business development at MorphoSys.
Liangsu Wang
Co-Founder and CSO,
Caldera Therapeutics
Dr. Liangsu Wang is a biopharmaceutical executive and entrepreneur with nearly 30 years of experience in drug discovery, development, and R&D strategy. As Co-Founder and CSO of Caldera Therapeutics, she leads scientific strategy and portfolio development.
Previously, she founded BioSage Advisors and held senior leadership positions at Johnson & Johnson, Morphic Therapeutic, and Merck. At Johnson & Johnson, she was Vice President and Therapeutic Area Head of External Innovation, leading strategic partnerships and investments across multiple disease areas. At Morphic, she helped establish the company’s scientific strategy and pipeline, initiated its lead IBD program, MORF-057, and contributed to its financing and IPO; Eli Lilly acquired Morphic for $3.2 billion in 2024. Before Morphic, she was Executive Director and Head of Diabetes and NASH Discovery Research at Merck.
Dr. Wang holds a PhD from the University of Calgary and a BS from Fudan University.
Zhen Su
President and CEO,
Marengo Therapeutics
Dr. Zhen Su has been CEO and a member of the Board of Marengo Therapeutics since July 2021. Marengo’s lead program, invikafusp alfa (STAR0602), is a first-in-class bispecific dual T-cell agonist that selectively activates Vβ T-cell subsets together with an IL-2 signal. He has also served on the Board of Directors of Karyopharm Therapeutics since 2023.
Previously, Dr. Su was Senior Vice President and Global Head of the Oncology Business Franchise at Merck KGaA, and concurrently US Head of its Oncology Business Unit, and earlier Chief Medical Officer of EMD Serono. He held leadership roles of increasing responsibility at Sanofi Oncology and GSK. Earlier in his career, he was a faculty member at Duke University Medical School, where he led early oncology studies of mRNA-based and cell-based immunotherapy, and Director of the Cell and Gene Therapy program at the University of Florida.
Dr. Su received his MD from the Technical University of Dresden, Germany, and his MBA from the University of Toronto.
Dandan Dong
Managing Partner, TCGX Capital
Dr. Dandan Dong is a Managing Partner at TCGX, which closed its oversubscribed $600 million Asia Life Sciences Fund I in October 2026. She joined TCGX to lead its venture formation effort and brings more than 15 years of global healthcare investment and biotech operating experience.
Before TCGX, Dr. Dong was Chief Business Officer of ArriVent Biopharma, where she played an essential role in company formation, acquired the ex-China rights to its core asset, furmonertinib, and was instrumental in the company’s private and public financings.
Earlier, she was Managing Director at Vivo Capital and General Partner of the Vivo PANDA Fund and Innovation Fund II. She incubated cross-border biotech companies including Visen Pharmaceuticals, a joint venture with Ascendis Pharma, where as founding CBO and executive board member she led pipeline acquisition, corporate strategy, recruitment, and financing. She also co-founded RareStone Group, the first rare disease ecosystem in Greater China.
主持人:
Leon ‘Jun’ Tang
PhD, MS, ISWT Community
Dr. Leon ‘Jun’ Tang is the founding partner of InScienceWeTrust BioAdvisory (ISWT BioAdvisory), a life sciences consulting firm focused on East-West cross-border BD&L and R&D collaboration, which has advised more than 30 biotech companies, investment funds, and other life sciences companies. Since February 2026, he has also served as Vice President of the Mianus Accelerator at Mianus Capital, focusing on early-stage biotech investment and first-in-human clinical development.
Dr. Tang founded iSWT Community, a U.S.-based nonprofit with more than 5,000 active members from the Asian biotech community, and hosts the BioVerse webinar series. Previously, he was Head of BD Search & Evaluation at Shanghai Henlius Biotech, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager at the philanthropic venture fund of the Cancer Research Institute.
He has published more than 50 papers in journals including Nature Reviews Drug Discovery, Lancet Oncology, and Science Translational Medicine. He received his bachelor’s degree from Tianjin University, his master’s degree from Nankai University, and his PhD from the Icahn School of Medicine at Mount Sinai, and completed postdoctoral training at Memorial Sloan Kettering Cancer Center.
《大国新药》为什么要做国际版
自2021年《大国新药》正式开播以来,我们对谈了百余位嘉宾,记录了中国创新药从"跟跑"到"并跑"的每一步。
如今,中国生物医药产业已完成范式升级:License‑out 交易总额突破千亿美元,实现从创新 “引进来” 到成果 “走出去” 的转变,本土临床、CDMO 供应链深度融入全球,从产品出海走向参与全球创新共建,收获海外药企主动合作。但中外仍存在认知壁垒,海外对中国创新仍存有低成本、快交付的刻板印象,国内企业也有 “授权出海即落地” 的误区,双方缺少平等深度的交流。
在此背景下,《大国新药》正式推出国际版,由凯莱英生物、E药经理人、微解药联合主办,聚焦医药创新全球化,打造中西方创新者平等对话的专业平台。
一审| 石宛佳
二审| 李芳晨
三审| 李静芝